Top

Published in:

01-10-2005 | Original Article

The inhibitory effect of disease-modifying anti-rheumatic drugs and steroids on gliostatin/platelet-derived endothelial cell growth factor production in human fibroblast-like synoviocytes

Authors: Takuma Kusabe, Yuko Waguri-Nagaya, Tomohiro Tanikawa, Mineyoshi Aoyama, Muneyoshi Fukuoka, Masaaki Kobayashi, Takanobu Otsuka, Kiyofumi Asai

Published in: Rheumatology International | Issue 8/2005

Abstract

Gliostatin/platelet-derived endothelial cell growth factor (GLS/PD-ECGF) is known to have both angiogenic and arthritogenic activities. The purpose of this study was to investigate whether disease-modifying anti-rheumatic drugs (DMARDs) and steroids are involved in the regulation of GLS expression. Fibroblast-like synoviocytes (FLSs) obtained from patients with rheumatoid arthritis (RA) were cultured and stimulated by interleukin (IL)-1β with or without DMARDs and steroids. The expression levels of GLS were determined using the reverse transcription-polymerase chain reaction and an ELISA. In cultured rheumatoid FLSs, the expression of GLS mRNA was significantly increased by stimulation with IL-1β. By contrast, GLS mRNA levels in IL-1β-stimulated FLSs were reduced by treatment with aurothioglucose (AuTG) and dexamethasone (DEX). These findings indicate that AuTG and DEX have anti-rheumatic activity, which is mediated via the suppression of GLS production. Neither methotrexate (MTX) nor sulfasalazine (SSZ) had a significant influence on GLS levels in our study.

Paleolog EM (1996) Angiogenesis: a critical process in the pathogenesis of RA—a role for VEGF? Br J Rheumatol 35:917–919CrossRefPubMed

Szekanecz Z, Koch AE, Kunkel SL, Strieter RM (1998) Cytokines in rheumatoid arthritis. Potential targets for pharmacological intervention. Drugs Aging 12:377–390PubMed

Asai K, Hirano T, Matsukawa K, Kusada J, Takeuchi M, Otsuka T, Matsui N, Kato T (1993) High concentration of immunoreactive gliostatin/platelet-derived endothelial cell growth factor in synovial fluid and serum of rheumatoid arthritis. Clin Chim Acta 218:1–4

Takeuchi M, Otsuka T, Matsui N, Asai K, Hirano T, Moriyama A, Isobe I, Eksioglu YZ, Matsukawa K, Kato T, Tada T (1994) Aberrant production of gliostatin/platelet-derived endothelial cell growth factor in rheumatoid arthritis. Arthritis Rheum 37:662–672PubMed

Waguri Y, Otsuka T, Sugimura I, Matsui N, Asai K, Moriyama A, Kato T (1997) Gliostatin/platelet-derived endothelial cell growth factor as a clinical marker of rheumatoid arthritis and its regulation in fibroblast like synoviocytes. Br J Rheumatol 36:315–321CrossRefPubMed

Muro H, Waguri-Nagaya Y, Mukofujiwara Y, Iwahashi T, Otsuka T, Matsui N, Moriyama A, Asai K, Kato T (1999) Autocrine induction of gliostatin/platelet-derived endothelial cell growth factor (GLS/PD-ECGF) and GLS-induced expression of matrix metalloproteinases in rheumatoid arthritis synoviocytes. Rheumatol 38:1195–1202CrossRef

Waguri-Nagaya Y, Otsuka T, Sugimura I, Matsui N, Asai K, Nakajima K, Tada T, Akiyama S, Kato T (2000) Synovial inflammation and hyperplasia induced by gliostatin/ platelet-derived endothelial cell growth factor in rabbit knees. Rheumatol Int 20:13–19CrossRefPubMed

Ishikawa F, Miyazono K, Hellman U, Drexler D, Wernstedt C, Hagiwara K, Usuki K, Takaku F, Risau W, Heldin CH (1989) Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 338:557–562CrossRefPubMed

Moghaddam A, Zhang H-T, Fan T-P, Hu D-E, Lees VC, Turley H, Fox SB, Gatter KC, Harris AL, Bicknell R (1995) Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA 92:998–1002PubMed

10.

Miyadera K, Sumizawa T, Haraguchi M, Yoshida H, Konstanty W, Yamada Y, Akiyama S (1995) Role of thymidine phosphorylase activity in the angiogenic effect of platelet-derived endothelial cell growth factor/thymidine phosphorylase. Cancer Res 55:1687–1690PubMed

11.

Asai K, Hirano T, Kaneko S, Moriyama A, Nakanishi K, Isobe I, Eksioglu YZ, Kato T (1992) A novel glial growth inhibitory factor, gliostatin, derived from neurofibroma. J Neurochem 59:307–317PubMed

12.

Asai K, Nakanishi K, Isobe I, Eksioglu YZ, Hirano T, Hama K, Miyamoto T, Kato T (1992) Neurotrophic action of gliostatin on cortical neurons: identity of gliostatin and platelet-derived endothelial cell growth factor. J Biol Chem 267:20311–20316PubMed

13.

Furukawa T, Yoshimura A, Sumizawa T, Haraguchi M, Akiyama S (1992) Angiogenic factor. Nature 356:668CrossRefPubMed

14.

Arnett FC, Edworthy SM, Bloch DA, Mcshane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medger TA Jr, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMed

15.

Hirano T, Asai K, Matsukawa K Kato T, Takeuchi M, Yonezawa M, Otsuka T, Matsui N (1993) Establishment of enzyme immunoassay system for gliostatin/platelet-derived endothelial cell growth factor (PD-ECGF). Biochim Biophys Acta 1176:299–304

16.

Muro H, Waguri-Nagaya Y, Otsuka T, Matsui N, Asai K, Kato T (2001) Serum gliostatin levels in patients with rheumatoid factor-negative and factor-positive rheumatoid arthritis and changes of these levels after surgical treatment. Clin Rheumatol 20:331–336CrossRefPubMed

17.

Colville-Nash PR, Scott DL (1992) Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications. Ann Rheum Dis 51:919–925PubMed

18.

Seitz M, Dewald B, Ceska M, Gerber N, Baggiolini M (1992) Interleukin-8 in inflammatory rheumatic diseases: synovial fluid levels, relation to rheumatoid factors, production by mononuclear cells, and effects of gold sodium thiomalate and methotrexate. Rheumatol Int 12:159–164CrossRefPubMed

19.

Loetscher P, Dewald B, Baggiolini M, Seitz M (1994) Monocyte chemoattractant protein 1 and interleukin 8 production by rheumatoid synoviocytes. Effects of anti-rheumatic drugs. Cytokine 6:162–170CrossRefPubMed

20.

Deleuran B, Kristensen M, Paludan K, Zachariae C, Larsen CG, Zachariae E, Thestrup-Pedersen K (1992) The effect of second-line antirheumatic drugs on interleukin-8 mRNA synthesis and protein secretion in human endothelial cells. Cytokine 4:403–409CrossRef

21.

Yoshida S, Kato T, Sakurada S, Kurono C, Yang JP, Matsui N, Soji T, Okamoto T (1999) Inhibition of IL-6 and IL-8 induction from cultured rheumatoid synovial fibroblasts by treatment with aurothioglucose. Int Immunol 11:151–158CrossRefPubMed

22.

Mascarenhas BR, Granda JL, Freyberg RH (1972) Gold metabolism in patients with rheumatoid arthritis treated with gold compounds—reinvestigated. Arthritis Rheum 15:391–402PubMed

23.

Ikeda N, Adachi M, Taki T, Huang C, Hashida H, Takabayashi A, Sho M, Nakajima Y, Kanehiro H, Hisanaga M, Nakano H, Miyake M (1999) Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer 79:1553–1563CrossRefPubMed

24.

Maeda K, Kang SM, Ogawa M, Onoda N, Sawada T, Nakata B, Kato Y, Chung YS, Sowa M (1997) Combined analysis of vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression in gastric carcinoma. Int J Cancer 74:545–550CrossRefPubMed

25.

O’Byrne KJ, Koukourakis MI, Giatromanolaki A, Cox G, Turley H, Steward WP, Gatter K, Harris AL (2000) Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 82:1427–1432PubMed

26.

Toi M, Inada K, Hoshina S, Suzuki H, Kondo S, Tominaga T (1995) Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer. Clin Cancer Res 1:961–964PubMed

27.

Walsh DA (1999) Angiogenesis and arthritis. Rheumatology 38:103–12CrossRefPubMed

28.

Koch AE, Harlow LA, Haines GK, Amento EP, Unemori EN, Wong WL, Pope RM, Ferrara N (1994) Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 152:4149–4156PubMed

29.

Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, Berse B, Jackman RW, Senger DR, Dvorak HF, Brown LF (1994) Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 180:341–346CrossRefPubMed

30.

Nagashima M, Yoshino S, Ishiwata T, Asano G (1995) Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis. J Rheumatol 22:1624–1630PubMed

31.

Nagashima M, Yoshino S, Aono H, Takai M, Sasano M (1999) Inhibitory effects of anti-rheumatic drugs on vascular endothelial growth factor in cultured rheumatoid synovial cells. Clin Exp Immunol 116:360–365CrossRefPubMed

Title: The inhibitory effect of disease-modifying anti-rheumatic drugs and steroids on gliostatin/platelet-derived endothelial cell growth factor production in human fibroblast-like synoviocytes
Authors: Takuma Kusabe
Yuko Waguri-Nagaya
Tomohiro Tanikawa
Mineyoshi Aoyama
Muneyoshi Fukuoka
Masaaki Kobayashi
Takanobu Otsuka
Kiyofumi Asai
Publication date: 01-10-2005
Publisher: Springer-Verlag
Published in: Rheumatology International / Issue 8/2005
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-005-0624-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The inhibitory effect of disease-modifying anti-rheumatic drugs and steroids on gliostatin/platelet-derived endothelial cell growth factor production in human fibroblast-like synoviocytes

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2005

Sacroiliitis in familial Mediterranean fever and seronegative spondyloarthropathy: importance of differential diagnosis

Damage did not independently influence mortality in childhood systemic lupus erythematosus

Association of CYP17 gene polymorphism and rheumatoid arthritis in Chinese patients in central Taiwan

No relationship of −627 interleukin-10 promoter polymorphism in Chinese patients with rheumatoid arthritis

Severe, refractory type II essential mixed cryoglobulinemia treated with 2-chlorodeoxyadenosine and mycophenolate mofetil

Prevalence and risk factors of knee osteoarthritis in Huang-Pu District, Shanghai, China

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page